Entyvio safe and effective for UC in real-world study
An analysis of data from the VICTORY consortium through the University of California at San Diego, as published in The American Journal of Gastroenterology, found vedolizumab effective in ulcerative colitis. Cumulative rates of endoscopic remission and clinical remission were the main effectiveness outcomes of the review. Researchers analyzed secondary outcomes measures of cumulative rates of deep remission and steroid-free remission, along with serious adverse events, safety outcomes of serious infection and colectomy.
The study included adult patients (n = 321) with follow-up after starting vedolizumab for clinically active UC. The primary effectiveness outcomes of the review were cumulative rates of clinical remission and endoscopic remission. Researchers also included secondary outcomes measures of cumulative rates of steroid-free remission and deep remission, as well as safety outcomes of serious infection, serious adverse events and colectomy in their analysis.